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Edited by Beat ImhofAbstract C26, the C-terminal 26 residue peptide of serpin A1,
signiﬁcantly increased cell proliferation in cultures of hepatoma
cells, but not in porcine kidney epithelial cells, human skin
ﬁbroblasts or keratinocytes. The mitogenic activity of C26 was
preferentially inhibited with a protein kinase C (PKC) inhibitor,
an antibody against CD47 and CD47 short interfering RNA.
The mutant C26-K19R,N22M, imitating a thrombospondin-like
cell adhesion motif, increased the mitogenic activity in both Hep
G2 cells and MCF-7 breast cancer cells. Phosphorylation of C26
at T24 (a putative PKC phosphorylation site) resulted in a 1.9–
2.5 increase in mitogenic activity over C26 in MCF-7 cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Serpin A1, also known as a1-antitrypsin or a1-proteinase
inhibitor, is the best known and most abundant member of the
serpin family of proteinase inhibitors and plays a key role in
the control of homeostasis by neutralizing the deleterious ef-
fects of neutrophil elastase. This inhibition of serine protein-
ases may explain the action of serpin A1 in the suppression of
cell growth in breast cancer cells, because it prevents the pro-
teolytic release of membrane-bound transforming growth
factor-a [1]. In most instances, serpin A1 is actually a growth
factor in a variety of cells from epithelial, ﬁbroblastic and
hematopoietic origin [2–5]. We found that the mutation
M351E in a recombinant serpin A1 fusion protein increased
the anti-elastase activity without changing at all the mitogenic
activity associated with the inhibitor [5]. This observation
suggested that the mitogenic activity resides at a position dif-
ferent from the classical serpin active site loop. The only sec-
tion of serpin A1 known to have biological activity
independent of the active site loop is the C-terminal end of the
molecule. Proteolytic cleavage of serpin A1 results in the re-* Corresponding author. Fax: +1-514-843-1709.
E-mail address: luis.f.congote@muhc.mcgill.ca (L.F. Congote).
Abbreviations: C26, PFVFLMIEQNTKSPLFMGKVVNPTQK; C26p,
C26 phosphorylated at T24; C26t, PFVFLMIEQNTKSPLFMGRVV-
MPTQK; PKC, protein kinase C; EGF, epidermal growth factor;
4N1-1, RFYVVMWK; GAPDH, glycerylaldehyde-3-phosphate
dehydrogenase; siRNA, short interfering RNA
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doi:10.1016/j.febslet.2004.09.035lease of a peptide comprising the last 36 amino acids (C36).
This peptide has chemotactic activity [6], induces monocyte
activation with a concomitant increase of proinﬂammatory
cytokines [7], is a speciﬁc transcriptional downregulator of
enzymes involved in bile acid synthesis in vitro and in vivo [8]
and stimulates thymidine incorporation into ME 1477 mela-
noma cells [9]. We assumed that at least part of these biological
activities resides within the last 26 amino acids of the peptide.
In fact, the C-terminal 26 residue peptide contains the b-sheet
structure identiﬁed in the three dimensional serpin A1-trypsin
complex [10], as well as the binding site of the serpin–enzyme
complex to its putative receptor in Hep G2 cells [6]. In the
following study, we demonstrate that C26 is a mitogen for Hep
G2 and MCF-7 cells and identify two additional sections of the
molecule which could play a key role on cell proliferation.2. Materials and methods
2.1. Materials
All cell lines used in this study were from the American Tissue Type
Culture Collection, with the exception of human skin ﬁbroblasts
(Cambrex) and human skin keratinocytes (Invitrogen). Cell culture
media were obtained from Invitrogen and Sigma. Epidermal growth
factor (EGF) was from R & D systems. Serpin A1 and thrombo-
spondin 1 were from Calbiochem. Alamar Blue was from Biosource.
Albumin- and azide-free monoclonal antibodies against CD36 (clone
1A7), CD47 (clone B6H12.2) and b1-integrin (P5D2) were from Ne-
omarkers (CD36, CD47) and Santa Cruz Biotechnology (b1-integrin).
Myristoylated FARKGALRQ, a speciﬁc PKC inhibitor [11], was
obtained from Sigma. Pre-designed double-stranded CD47 siRNA
(ID#2811), GAPDH siRNA and siPORT amine were purchased from
Ambion.
2.2. Synthetic peptides
Synthetic peptides C26, C26p, C26t (Fig. 1) and RFYGGMWK
were obtained from the Sheldon Biotechnology Centre (McGill Uni-
versity, Montreal) and Alpha Diagnostic International. The peptides
were puriﬁed by HPLC and the molecular weight was conﬁrmed by
mass spectrometry. The structure of C26 was further conﬁrmed by
amino acid sequence analysis (Sheldon Biotechnology Centre). The
peptide 4N1-1 (RFYVVMWK) was obtained from Bachem. Performic
acid oxidation of C26 was done by mixing 1 vol of hydrogen peroxide
with 9 vol of 98% formic acid for 1 h. The formed performic acid was
used to oxidize the dried C26 peptide for 2 h on ice.
2.3. Cell proliferation
Cell proliferation was assessed with a spectrophotometric assay us-
ing Alamar Blue, as previously described [12]. Brieﬂy, cells were seeded
into 96-well plates at a concentration of 3000 (Hep G2), 8000 (MCF-7)
or 5000 (all other cultures) cells/well in 200 ll medium supplemented
with 10% fetal bovine serum (keratinocytes were cultured in kerati-
nocyte serum-free medium, Invitrogen). After 16 h, the monolayersblished by Elsevier B.V. All rights reserved.
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Fig. 1. Comparison of synthetic peptides based on the C-terminal
structure of serpin A1. C26, amino acid sequence of the last 26 amino
acids of serpin A1, showing in boxes the positions of FVFLM, the
motif interacting with the serpin-complex receptor and KVVN, a se-
quence homologous to a thrombospondin cell adhesion domain. The
3D structure was designed with the RasMol program. C26p, C26
phosphorylated at threonine 24, a putative PKC phosphorylation site.
TSP 7N3-1, the thrombospondin cell adhesion motif taken as a model
for C26t, a modiﬁed C26 containing four of the ﬁve amino acids of
TSP 7N3-1. TSP 4N1-1, the best studied peptide of thrombospondin,
known to interact with CD47, as described in Section 3.
344 L.F. Congote, N. Temmel / FEBS Letters 576 (2004) 343–347were washed two times with phosphate buﬀered saline containing
10 mM HEPES (pH 7.5) and incubated for 24 h with a serum-free
medium to quiesce the cells. We used the same incubation medium for
Hep G2 and MCF-7 cells. It was RPMI 1640 supplemented with 1 mM
sodium pyruvate, 0.1 mM MEM non-essential amino acids, 300 lg/ml
fatty acid free, tissue culture tested bovine serum albumin (Sigma),
5 lg/ml bovine transferrin (ICN) and 10 lg/ml gentamicin. The cells
were incubated with 100 ll of the peptide solutions prepared in this
serum-free medium. 48 h later, the state of cell proliferation was
measured as the increase in absorbance after an 8 h incubation with
10% (v/v) Alamar Blue in the serum-free medium. For siRNA exper-
iments, the serum free medium was as indicated above but contained
only 100 lg/ml albumin and no gentamicin. 4000 Hep G2 cells were
plated per well. The liposome–siRNA complexes were prepared as
indicated by the manufacturer (Ambion) and added to the cells only
during the 24 h-quiescence period (0.75 ll siPORT amine per 100 ll
medium per well). Cell proliferation was measured as indicated above.-30
0         0.1         1           10        100
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Fig. 2. Role of C26 in cell proliferation. (A) Comparison of the eﬀects
of C26 on cell proliferation in Hep G2 cultures before (closed squares)
and after (open squares) treatment with performic acid, using the Al-
amar Blue technique as described in Section 2.3. Results from one
representative experiment showing meanS.E.M. (n ¼ 4). (B) Sum-
mary of all experiments using diﬀerent cell lines. The results are
means S.E.M. expressed as percent stimulation over control cell
cultures. The squares correspond to the incubation of Hep G2 with
C26 (n ¼ 11) and oxidized C26 (n ¼ 5). Open triangles, cultures of
human skin keratinocytes (n ¼ 10–13). Closed triangles, Porcine kid-
ney epithelial cells (n ¼ 6). Circles, human skin ﬁbroblasts (n ¼ 8–9).
The stimulation of cell proliferation in Hep G2 cells was signiﬁcant
according to analysis of variance and Student–Newman–Keuls multi-
ple comparison test: P < 0:05 (5 lM), P < 0:001 (10 lM), P < 0:001
(20 lM). The inhibition observed with 20 lM C26 in skin ﬁbroblasts
was signiﬁcant (P < 0:05, paired t test).3. Results and discussion
Although the biologically active, naturally occurring C36
terminal peptide of serpin A1 has been the subject of numerous
studies, it is reasonable to assume that the active part of the
peptide is localized at the terminal end comprising the b-sheet
domain of the serpin A1–trypsin complex [10]. This structure
was identiﬁed with the automated protein homology-modeling
server ‘‘Swiss-Model’’ [13,14] of C26 and is depicted in Fig. 1.
The C26 peptide includes the sequence FVFLM, originally
identiﬁed by Joslin et al. [6] as the binding site to the serpin–
enzyme complex receptor. After uptake, C36 interacts directly
with transcription factors regulating bile acid synthesis. Mu-
tations of the FVFLM site destroy this interaction [8]. Analysis
of C26 with the Scanprosite program of Expasy (ca.exp-
asy.org) revealed a protein kinase phosphorylation site atthreonine 24. This ﬁnding would be irrelevant in a secreted
protein such as Serpin A1. However, this site could be acces-
sible for phosphorylation after uptake of the C-terminal
peptide.
We investigated ﬁrst the mitogenic activity of C26 (Fig. 2).
The highest concentration tested (20 lM) is within the normal
concentrations of serpin A1 in plasma. Under pathological
conditions, such as acute leukemia, this concentration (in-
cluding serpin A1 and serpin A1–elastase complexes) is sub-
stantially increased [15]. Fig. 2A shows that the peptide was
able to stimulate cell proliferation in Hep G2 cells, one of the
best-known target cells of C36. The degree of stimulation after
a 48 h incubation in serum-free medium was substantial (55%
over controls), because the well known Hep G2 mitogen EGF
(20 nM) stimulated cell proliferation by only 42.2 14% over
controls under identical conditions (mean S.E.M., P < 0:05,
n ¼ 8). It is unlikely that blocking the inhibitory activity of
endogenous serpin A1 may cause the C26-mediated increase in
cell numbers. First, this serpin, at a concentration of 20 nM,
known to signiﬁcantly increase cell proliferation of HL60
cultures [5]was not inhibitory in Hep G2 cells (1.5 5.6%
stimulation over controls, n ¼ 5). Furthermore, the amount of
Serpin A1 produced by Hep G2 cells in the serum-free con-
ditions described here was very low (0.3 nM), as measured
with a serpin A1 ELISA [16]. The mitogenic activity of C26
025
50
75
100
0.2 1 10 500
PKC inhibitor [µM]
Antibody [µg/ml]
In
hi
bi
tio
n 
[%
]
A
B
C
0.001 0.01 0.1 1 10
50
75
100
125
0
0 20 100
0
20
40
60
80
100
siRNA  [nM]
C2
6 
[%
 in
cre
as
e
ov
e
r 
co
n
tro
ls
]
Fig. 3. Eﬀect of protein kinase inhibitor, antibodies against CD36 and
CD47 and small interference RNA for CD47 on the C26-mediated
stimulation of cell proliferation. (A) Hep G2 cells were treated with 20
lM C26 (closed squares) or 20 nM EGF (circles) and increasing
concentrations of the PKC inhibitor described in Section 2.1.
Mean S.E.M. (n ¼ 7). The decrease observed in the presence of 5 lM
PKC inhibitor was signiﬁcantly lower in cells treated with C26 as
compared with those treated with EGF (P < 0:025, paired t test). (B)
Representative experiments indicating the eﬀect of increasing concen-
trations of antibodies against CD36 (circles) or CD47 (squares) in
control cell cultures (white) and cultures in the presence of C26 (black).
Mean S.E.M. of triplicate determinations. Further experiments in-
dicated that the inhibition of C26-mediated cell proliferation by the
antibody against CD47 as compared to controls was signiﬁcant
(P < 0:05) at the concentrations of 0.04, 0.2 and 1 lg/ml (n ¼ 4,
analysis of variance and Student–Newman–Keuls multiple compari-
sons test). (C) Hep G2 cells were transfected with increasing concen-
trations of CD47 siRNA (squares) and GAPDH siRNA as a control
siRNA (triangles). One day after transfection C26 (20 lM) was added.
Cell proliferation was measured by adding Alamar Blue after 48 h and
continuing the incubation for 24 h. The diﬀerence between the re-
duction of the C26-mediated increase in cell proliferation using
100 nM CD47 siRNA as compared with that observed with 100 nM
GAPDH siRNA was signiﬁcant (P ¼ 0:031, Wilcoxon test, n ¼ 6).
L.F. Congote, N. Temmel / FEBS Letters 576 (2004) 343–347 345was lost after performic acid oxidation, probably due to the
presence of two methionines at the two opposite sites of the
hairpin structure of C26, one of them within the putative
binding site of the serpin–enzyme complex receptor. The mi-
togenic activity was rather speciﬁc for hepatoma cells, because
no signiﬁcant increase of cell proliferation could be seen in
human skin ﬁbroblasts or porcine kidney epithelial cells
(Fig. 2B). The increase of keratinocytes observed in the pres-
ence of 20 lM C26 was non-signiﬁcant. Surprisingly, the de-
crease in cell numbers in cultures of skin ﬁbroblasts at the
same concentration was signiﬁcant (P < 0:05, paired t test,
n ¼ 8). These experiments suggest that the mitogenic action of
C26 is particularly relevant in cancerous epithelial cells, with
no signiﬁcant changes in normal epithelial cells and a mar-
ginal, but signiﬁcant decrease in skin ﬁbroblasts at the highest
concentration tested.
We investigated the possible involvement of PKC on the
action of C26 on cell proliferation. Hep G2 cells were incu-
bated with 20 nM EGF or 20 lM C26 in the presence of in-
creasing concentrations of myristoylated FARKGALRG, a
speciﬁc PKC inhibitor. The cells were incubated as usual for
48 h and proliferation was measured with the Alamar Blue
technique (Fig. 3A). The results are expressed as percent in-
hibition as compared with the action of the growth factors
alone (¼ 100%). The mitogenic activity of C26 was signiﬁ-
cantly more sensitive to the action of the inhibitor than that
observed with EGF. These results suggest that PKC plays a
more important role in the mitogenic action of the peptide
than that observed in EGF signaling. This could have some-
thing to do with the PKC phosphorylation site at T24 in C26,
as will be discussed later.
Uptake of the serpin A1 terminal peptide alone or as part of
the serpin–enzyme complex has been studied in diﬀerent cell
lines, including hepatoma cells and monocytes. Three mem-
brane receptors have been implicated in this process: the ser-
pin–enzyme complex receptor, the LDL receptor and the
multifunctional CD36 scavenger receptor [6,17,18]. We inves-
tigated the involvement of CD36 (also known as the throm-
bospondin receptor) by incubating the cells with and without
C26 in the presence of a speciﬁc blocking antibody against
CD36 (Fig. 3B, circles). As a control, we used an antibody
against CD47, known to recognize a diﬀerent peptide motif of
thrombospondins (Fig. 3B, squares). Surprisingly, the CD36
antibody did not have any eﬀect on the action of C26 on cell
proliferation, whereas the antibody against CD47 signiﬁcantly
reduced the proliferating eﬀects of C26. These results suggest
that CD47 (also known as the integrin-associated protein,
IAP) is involved in the action of the peptide. It could be argued
that the CD47 antibody could act not only as a function
blocker but also as a ligand. Therefore, we tested the action of
another antibody which blocks b1-integrins, membrane re-
ceptors mediating the action of thrombospondin in MCF-7
cells [19] and modulating the action of CD47 in smooth muscle
cells [20]. The inhibition of C26-mediated cell proliferation by
the antibody against b1-integrin (73 8%) as compared to
controls (95 10) was signiﬁcant (Wilcoxon test, P < 0:04,
n ¼ 6) at an antibody concentration of 0.02 lg/ml. A more
direct evidence of the involvement of CD47 in the action of
C26 can be obtained by a sequence-speciﬁc, postranscripional
gene silencing of CD47 with the method of RNA interference
[21] (Fig. 3C). Hep G2 cells were transfected with small in-
terference RNA (siRNA) for silencing GAPDH (a well-established control siRNA) and CD47 (designed using an
algorithm developed by Cenix Bioscience-Ambion). The lipo-
some mixture was removed and the cells were incubated for
48 h with C26 followed by a 24 h incubation with Alamar
blue. The C26-mediated stimulation of cell proliferation was
020
40
60
80
1 10 200 2.5        5
0
20
40
60
1 10 200 2.5        5
Concentration [µM]
%
 o
f c
on
tro
ls
A
B
Fig. 4. Comparison of the eﬀects of C26, C26p, C26t and 4N1-1 on cell
proliferation. Hep G2 cells (A) and MCF-7 cells (B) were treated with
increasing concentrations of the peptides and cell proliferation was
measured as indicated in Section 2.3. The results are expressed as
mean S.E.M. of six experiments in Hep G2 cells (except for the in-
cubations of 4N1-1, n ¼ 5) and of 5 experiments with MCF-7 cells.
C26, closed squares. Phosphorylated C26 (C26p), open squares. C26
with a thrombospondin-like motif (C26t), circles. 4N1-1, triangles.
Analysis of variance and Student–Newman–Keuls multiple compari-
sons test indicated that in Hep G2 cells, the stimulation of cell pro-
liferation by C26, C26p and C26t was signiﬁcant (P < 0:001 for 20 lM,
P < 0:001 for 10 lM C26 or C26p, P < 0:001 for 5 lM C26t, P < 0:01
for 10 lM C26t and P < 0:05 for 5 lM C26p). In Hep G2 cells, C26t
had a signiﬁcantly higher stimulation than that observed with C26 at
5 lM (P < 0:01) or 5 lM C26p (P < 0:05). In Hep G2 cells, the dif-
ferences between C26 and C26p were non-signiﬁcant and the stimu-
lation caused by 4N1-1 was non-signiﬁcant. In MCF-7 cells (B), the
stimulation of cell proliferation by C26, C26p and C26t was signiﬁcant
(P < 0:001 for all concentrations (2.5–20 lM), except for 2.5, 5 and
20 lM C26 (P < 0:01) and 2.5 lM C26t, P < 0:01). C26t had a sig-
niﬁcantly higher stimulation than that observed with C26 at 20 lM
(P < 0:05). At 10 and 20 lM,C26p produced a signiﬁcantly higher cell
proliferation than that observed with C26 (P < 0:001). The stimulation
observed with 4N1-1 in MCF-7 cells was signiﬁcant (5 lM and 10 lM,
P < 0:05; 20 lM, P < 0:01).
346 L.F. Congote, N. Temmel / FEBS Letters 576 (2004) 343–347signiﬁcantly inhibited with 100 nM CD47–siRNA as compared
with the eﬀects seen with 100 nM GAPDH–siRNA (P ¼ 0:031,
Wilcoxon test, n ¼ 6).
An analysis of the amino acid sequence of C26 revealed the
presence of a KVVN motif, similar to the thrombospondin
C-terminal cell adhesion motifs identiﬁed by Kosfeld and
Frazier [22] with the synthetic peptides 7N3-1 and 4N1-1,
shown in Fig. 1. The recently elucidated 3D structure of the C-
terminal domain of thrombospondin 1 [23] indicates that both
VVM peptides are also associated with b-sheet domains. In
order to conﬁrm the involvement of CD47 and the PKC
phosphorylation site on the action of C26, we synthesized two
C26 analogs: C26p, containing a phosphate group at T24 and
C26t, in which K19 and N22 are substituted by R19 and M22.
This creates the motif RVVM, containing four of the ﬁve
amino acids of 7N3-1. Although 4N1-1 has been the peptide of
choice for studies in connection with the integrin-associated
protein CD47, we preferred to mimic the 7N3-1 motif, which
required the change of only two amino acids.
Until now, a possible role of the serpin A1 terminal peptide
on cell proliferation or thymidine incorporation has been ob-
served only in cancer cell lines, such as the hepatoma cell line
Hep G2, as described in this paper, and the melanoma cell line
ME 1477 [9]. We thought that the breast cancer cell line MCF-7
could be a target for C26, because it shares many of the
properties of Hep G2 cells. In fact, both cell lines are carcino-
mas (epithelial cell origin) and can synthesize large amounts of
serpin A1 [1,24,25]. Therefore, C26, C26p, C26t and the com-
mercially available thrombospondin-peptide 4N1-1 were added
to cultures of Hep G2 and MCF-7 and the changes in cell
proliferation were measured as indicated in Section 2.3. The
three C26 peptides signiﬁcantly stimulated cell growth in both
Hep G2 and MCF-7 cells. In general, the modiﬁed peptides
C26t and C26p had a higher mitogenic activity than C26, but
the eﬀects were quite diﬀerent in the two cell lines. C21t, the
peptide with the thrombospondin motif, signiﬁcantly increased
cell proliferation as compared with C26 in Hep G2 cells (5 lM,
P < 0:01) and MCF-7 cells (20 lM, P < 0:05). The action of
C26t was more eﬀective in Hep G2 cells, corresponding to a
shift of the dose–response curve towards low concentrations.
This was not the case with the phosphorylated peptide, which
did not signiﬁcantly increase cell proliferation as compared
with the eﬀects of C26 (Fig. 4A). On the contrary, the mitogenic
action of the phosphorylated peptide C26p was 1.9–2.5 times
higher than that of C26 in MCF-7 cells (10 lM, P < 0:001; 20
lM, P < 0:001). In Hep G2 cells, the thrombospondin peptide
4N1-1 had no signiﬁcant eﬀect on cell proliferation. These re-
sults suggest that the attachment of the thrombospondin-like
motif to the C26 b-hairpin plays a key role in the mitogenic
activity, because it can not be eﬃciently replaced with the small
thrombospondin peptide. We have also found that thrombo-
spondin 1 (2 nM), under conditions which stimulate skin ﬁ-
broblast cell proliferation (Congote et al., in preparation), did
not have any signiﬁcant eﬀect in Hep G2 cells (1 4.6% stim-
ulation over controls, n ¼ 7). Furthermore, we were not able to
detect any endogenous thrombospondin 1 in the medium
conditioned by Hep G2 cells using an ELISA (limit of detection
¼ 0.7nM). In MCF-7 cells, 4N1-1 by itself had a low, but
signiﬁcant mitogenic activity in this cell line. This could not be
observed with a control peptide RFYGGMWK (20 lM, results
not shown). It is unlikely that CD47 is directly involved in
peptide uptake by internalization. This is the function of theother serpin A1-C36 receptors described above. However,
CD47 could have a synergistic eﬀect with the other receptors.
The best example of this synergistic function of CD47 is the
CD47-mediated enhancement of IGF-I receptor signaling in
smooth muscle cells [26]. In this system, the VVM peptides of
thrombospondin delay the de-phosphorylation of IGF-I re-
ceptors, enhancing downstream signaling.
In summary, we have shown that the mitogenic activity of
the C-terminal section of serpin A1 is localized within the last
26 amino acids. The activity of the peptide is sensitive to PKC
inhibitors and T24 phosphorylation resulted in a signiﬁcant
increase of activity in MCF-7 cells. The mitogenic activity is
increased by mutations mimicking a thrombospondin adhe-
sion motif and inhibited with antibodies against the throm-
bospondin-binding membrane protein CD47.
Serpin A1 plays a key role in the neutralization of neutrophil
elastase. Problems arise at the moment when the balance ser-
pin-elastase is destroyed. Tumor growth and metastasis in-
L.F. Congote, N. Temmel / FEBS Letters 576 (2004) 343–347 347volving breast cancer cells could be enhanced at sites of high
proteolytic activity, in which there is an excess of serine pro-
teases over serpin A1. This would lead to release of trans-
forming growth factor-b [1], conversion of all available serpin
A1 to serpin–enzyme complexes, binding and uptake of the
C-terminal peptide and stimulation of cell proliferation.Acknowledgements: We thank Dr. Hugh Bennett for his advice on
peptide isolation and performic acid oxidation. This work was sup-
ported by the Bayer-Canadian Blood Services-Hema Quebec-CIHR
Partnership Fund.References
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